A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV‐related HCC treated with sorafenib

Abstract

In patients with advanced HBV-related HCC treated with sorafenib, a high baseline HBV load was an adverse prognostic factor for survival. However, survival was significantly improved with the use of antiviral therapy.